NO753246L - - Google Patents
Info
- Publication number
- NO753246L NO753246L NO753246A NO753246A NO753246L NO 753246 L NO753246 L NO 753246L NO 753246 A NO753246 A NO 753246A NO 753246 A NO753246 A NO 753246A NO 753246 L NO753246 L NO 753246L
- Authority
- NO
- Norway
- Prior art keywords
- ethyl
- phenyl
- amine
- diphenyl
- benzhydryl
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 15
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 claims description 14
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 claims description 13
- -1 3,3-diphenylpropyl alcohol Chemical compound 0.000 claims description 11
- 230000002829 reductive effect Effects 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- HMGXPQXMLSOTJS-UHFFFAOYSA-N 3,3-diphenyl-n-(1-phenylethyl)propanamide Chemical compound C=1C=CC=CC=1C(C)NC(=O)CC(C=1C=CC=CC=1)C1=CC=CC=C1 HMGXPQXMLSOTJS-UHFFFAOYSA-N 0.000 claims description 5
- NENUCJVGUPDXPC-UHFFFAOYSA-N 3,3-diphenylpropyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NENUCJVGUPDXPC-UHFFFAOYSA-N 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 4
- 239000012429 reaction media Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 229910052987 metal hydride Inorganic materials 0.000 claims description 3
- 150000004681 metal hydrides Chemical class 0.000 claims description 3
- BZQGAPWJKAYCHR-UHFFFAOYSA-N 3,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)C1=CC=CC=C1 BZQGAPWJKAYCHR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000000155 melt Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000003509 tertiary alcohols Chemical class 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229960002602 fendiline Drugs 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- NJXWZWXCHBNOOG-UHFFFAOYSA-N 3,3-diphenylpropyl(1-phenylethyl)azanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(C)[NH2+]CCC(C=1C=CC=CC=1)C1=CC=CC=C1 NJXWZWXCHBNOOG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000007818 Grignard reagent Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical class CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 3
- SLHSRCBFPHCSGL-UHFFFAOYSA-N (3-bromo-1-phenylpropyl)benzene Chemical compound C=1C=CC=CC=1C(CCBr)C1=CC=CC=C1 SLHSRCBFPHCSGL-UHFFFAOYSA-N 0.000 description 2
- UYXDQUAGGZJICS-UHFFFAOYSA-N 3,3-diphenylpropanoyl chloride Chemical compound C=1C=CC=CC=1C(CC(=O)Cl)C1=CC=CC=C1 UYXDQUAGGZJICS-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical class OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Emergency Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUCI1510A HU169507B (hu) | 1974-09-25 | 1974-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO753246L true NO753246L (hu) | 1976-03-26 |
Family
ID=10994536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO753246A NO753246L (hu) | 1974-09-25 | 1975-09-24 |
Country Status (22)
| Country | Link |
|---|---|
| JP (1) | JPS5159843A (hu) |
| AR (2) | AR210586A1 (hu) |
| AT (1) | AT337675B (hu) |
| AU (1) | AU497358B2 (hu) |
| BE (1) | BE833824A (hu) |
| CH (2) | CH609323A5 (hu) |
| CS (2) | CS186749B2 (hu) |
| DD (1) | DD124874A5 (hu) |
| DE (1) | DE2541184C2 (hu) |
| DK (1) | DK429075A (hu) |
| FI (1) | FI752595A (hu) |
| FR (1) | FR2285865A1 (hu) |
| GB (1) | GB1464209A (hu) |
| HU (1) | HU169507B (hu) |
| IL (1) | IL48120A (hu) |
| IN (1) | IN141186B (hu) |
| NL (1) | NL7511183A (hu) |
| NO (1) | NO753246L (hu) |
| PL (2) | PL108111B1 (hu) |
| SE (1) | SE7510611L (hu) |
| SU (2) | SU603331A3 (hu) |
| YU (2) | YU37112B (hu) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2862103D1 (en) * | 1977-08-19 | 1982-11-18 | Sandoz Ag | Propenyl amines, processes for their production and pharmaceutical compositions containing them |
| FR2504524A1 (fr) * | 1981-04-22 | 1982-10-29 | Spofa Vereinigte Pharma Werke | N-(1-phenylethyl)-n-(3,3-diphenylpropyl)-hydroxylamines et procede pour leur preparation |
| US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) * | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5858684A (en) * | 1991-08-23 | 1999-01-12 | The Brigham And Women's Hospital, Inc. | Method of screening calcium receptor-active molecules |
| US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
| US6001884A (en) * | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5962314A (en) * | 1993-02-23 | 1999-10-05 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| DK1203761T3 (da) * | 1994-12-08 | 2005-04-11 | Nps Pharma Inc | Calciumreceptoraktive forbindelser |
| US6057346A (en) * | 1994-12-12 | 2000-05-02 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of retroviral LTR promoters by calcium response modifiers |
| US5981599A (en) | 1996-05-01 | 1999-11-09 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor active compounds |
| US20150344407A1 (en) * | 2012-08-21 | 2015-12-03 | The Board Of Regents Of The University Of Texas System | Fendiline derivatives and methods of use thereof |
| RU2739376C1 (ru) * | 2020-07-24 | 2020-12-23 | Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) | Способ получения фендилина |
-
1974
- 1974-09-25 HU HUCI1510A patent/HU169507B/hu unknown
-
1975
- 1975-09-16 CS CS7700003090A patent/CS186749B2/cs unknown
- 1975-09-16 DE DE2541184A patent/DE2541184C2/de not_active Expired
- 1975-09-16 CS CS7500006278A patent/CS186718B2/cs unknown
- 1975-09-17 IL IL48120A patent/IL48120A/xx unknown
- 1975-09-17 AT AT711175A patent/AT337675B/de active
- 1975-09-17 FI FI752595A patent/FI752595A/fi not_active Application Discontinuation
- 1975-09-18 IN IN1788/CAL/1975A patent/IN141186B/en unknown
- 1975-09-18 AU AU84956/75A patent/AU497358B2/en not_active Expired
- 1975-09-22 SE SE7510611A patent/SE7510611L/xx not_active Application Discontinuation
- 1975-09-23 FR FR7529069A patent/FR2285865A1/fr active Granted
- 1975-09-23 NL NL7511183A patent/NL7511183A/xx not_active Application Discontinuation
- 1975-09-23 JP JP50115476A patent/JPS5159843A/ja active Pending
- 1975-09-23 DD DD188496A patent/DD124874A5/xx unknown
- 1975-09-24 PL PL1975197355A patent/PL108111B1/pl unknown
- 1975-09-24 GB GB3915075A patent/GB1464209A/en not_active Expired
- 1975-09-24 DK DK429075A patent/DK429075A/da unknown
- 1975-09-24 CH CH950277A patent/CH609323A5/xx not_active IP Right Cessation
- 1975-09-24 PL PL1975183553A patent/PL107557B1/pl unknown
- 1975-09-24 NO NO753246A patent/NO753246L/no unknown
- 1975-09-24 CH CH1237175A patent/CH596139A5/xx not_active IP Right Cessation
- 1975-09-24 AR AR260504A patent/AR210586A1/es active
- 1975-09-24 YU YU2394/75A patent/YU37112B/xx unknown
- 1975-09-25 BE BE160382A patent/BE833824A/xx not_active IP Right Cessation
- 1975-09-25 SU SU752174852A patent/SU603331A3/ru active
-
1976
- 1976-08-03 SU SU762386655A patent/SU837319A3/ru active
- 1976-11-26 AR AR265488A patent/AR211558A1/es active
-
1981
- 1981-11-04 YU YU2611/81A patent/YU37115B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CH596139A5 (hu) | 1978-02-28 |
| DK429075A (da) | 1976-03-26 |
| AU8495675A (en) | 1977-03-24 |
| YU37115B (en) | 1984-08-31 |
| DD124874A5 (hu) | 1977-03-16 |
| BE833824A (fr) | 1976-01-16 |
| FI752595A (hu) | 1976-03-26 |
| CS186749B2 (en) | 1978-12-29 |
| AT337675B (de) | 1977-07-11 |
| YU261181A (en) | 1983-04-27 |
| HU169507B (hu) | 1976-12-28 |
| JPS5159843A (en) | 1976-05-25 |
| YU239475A (en) | 1983-04-27 |
| CH609323A5 (en) | 1979-02-28 |
| GB1464209A (en) | 1977-02-09 |
| DE2541184C2 (de) | 1984-05-10 |
| SU603331A3 (ru) | 1978-04-15 |
| PL108111B1 (pl) | 1980-03-31 |
| NL7511183A (nl) | 1976-03-29 |
| DE2541184A1 (de) | 1976-04-15 |
| AR211558A1 (es) | 1978-01-30 |
| AR210586A1 (es) | 1977-08-31 |
| FR2285865A1 (fr) | 1976-04-23 |
| PL107557B1 (pl) | 1980-02-29 |
| IL48120A0 (en) | 1975-11-25 |
| ATA711175A (de) | 1976-11-15 |
| CS186718B2 (en) | 1978-12-29 |
| IL48120A (en) | 1979-05-31 |
| YU37112B (en) | 1984-08-31 |
| SE7510611L (sv) | 1976-03-26 |
| AU497358B2 (en) | 1978-12-07 |
| FR2285865B1 (hu) | 1980-05-30 |
| IN141186B (hu) | 1977-01-29 |
| SU837319A3 (ru) | 1981-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0811002B1 (en) | Benzylpiperidines and piperazines as muscarinic antagonists | |
| NO753246L (hu) | ||
| SU588916A3 (ru) | Способ получени 2-тетрагидрофурил-6,7-бензоморфанов или их солей | |
| IE862802L (en) | Crystalline paroxetine | |
| US5728885A (en) | Method of preparing the enantiomers of O-dimethyltramadol | |
| EP1888571A2 (en) | New salt and polymorphs of a dpp-iv inhibitor | |
| US8198485B2 (en) | Resolution of 4,5-dimethoxy-1-(methylaminomenthyl)-benzocyclobutane | |
| HU193161B (en) | Process for preparing new n-alkyl-norscopines | |
| DK162629B (da) | 2-substituerede 1-aralkyl-imidazoler og farmaceutiske midler der indeholder disse, anvendelse heraf til fremstilling af farmaceutiske midler samt fremgangsmaade til fremstilling heraf | |
| WO2008035381A2 (en) | Process for the preparation of amine derivatives as calcimimetics | |
| KR20050083764A (ko) | (ｓ,ｓ)-시스-2-벤즈하이드릴-3-벤질아미노퀴누클리딘의제조 방법 | |
| EP0334538B1 (en) | Therapeutically useful tetralin derivatives | |
| DK200200339U3 (da) | Racemisk tamsulosin og tamsulosin i form af en fri base | |
| US5214156A (en) | Therapeutically useful tetralin derivatives | |
| PT93218B (pt) | Processo para a preparacao de 2-amino-1,2,3,4-tetra-idronaftalenos e 3-aminocromanos substituidos no anel | |
| US6384227B2 (en) | Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents | |
| EP0804417B1 (en) | Racemisation process for use in the manufacture of levobupivacaine and related piperidinecarboxanilide anaesthetic agents | |
| EP0452390B1 (en) | Halo substituted aminotetralins | |
| CZ181891A3 (en) | Hexahydroazepine derivatives | |
| WO1999061425A1 (en) | Processes and intermediates for preparing 2-substituted piperidine stereoisomers | |
| US20110230663A1 (en) | Process for the preparation of donepezil hydrochloride | |
| CN111943945B (zh) | 一种苏沃雷生中间体及其制备方法 | |
| DK170331B1 (da) | Fremgangsmåde til fremstilling af rimantadin | |
| CZ20011465A3 (cs) | Způsob přípravy 4-arylpiperidin-3-methanolů a příbuzných sloučenin | |
| CA2227912A1 (en) | Benzenesulphonamide derivatives, their preparation and their application in therapy |